Maxim Group Maintains Ocugen(OCGN.US) With Buy Rating, Maintains Target Price $4
Ocugen Is Maintained at Buy by Chardan Capital
Ocugen Doses First Subject in Phase I Trial of Diabetic Macular Oedema Treatment
Express News | Ocugen Inc - to Pursue Approval for Ocu200 as First-Line Therapy for Dme, DR, and Wet AMD
Express News | Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Ocu200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
